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Background: The best strategy to perform follow-up of patients with multiple cerebral
cavernous malformations (mCCM) is unclear due to the unpredictable clinical course.
Still, serial radiological follow-up is often performed. The objective of this work was to
critically question whether active follow-up by serial imaging is justified and has an impact
on clinical decision making.
Methods: We included all consecutive patients with mCCM treated and followed at
our Department between 2006 and 2016. Patient data were collected and analyzed
retrospectively.
Results: From a total number of 406 patients with CCM, n = 73 [18.0%; mean age at
first diagnosis 45.2 years (±2.4 SE); n = 42 male (57.5 %)] were found to harbor multiple
lesions (≤5 CCM in 58.9%; 6–25 in 21.9%;≥ 25 in 19.2%). All of themwere followed for a
mean of 6.8 years (±0.85 SE). Conservative treatment was suggested in 43 patients over
the complete follow-up period. Thirty patients underwent surgical extirpation of at least
one CCM lesion. Forty-three surgical procedures were performed in total. During 500.5
follow-up years in total, routinely performed follow-up MRI in asymptomatic patients lead
to an indication for surgery in only two occasions and even those two were questionable
surgical indications.
Conclusion: Routinely performed follow-up MRI in asymptomatic patients with mCCM
is highly questionable as there is no evidence for therapeutic relevance.
Keywords: cerebral cavernous malformation, CM, mCCM, cavernoma, cavernous angioma, cavernous
hemangioma, follow-up
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INTRODUCTION
CCM are the most common vascular malformations in the
brain with an incidence of ∼0.4–0.6% (1, 2). The clinical
presentation of patients with CCM ranges from incidental
findings in MRI to symptomatic courses with focal neurologic
deficits and epilepsy (2). While patients with single lesions
often have a sporadic form of the disease, the number of
patients harboring multifocal lesions, associated with familial
CCM (FCCM), is high (10–31% of all cases). The principle
danger inherent to CCM is the hemorrhage risk that has
been estimated around 0.6–2% per lesion-year or 4.3–13% per
patient-year in prospective studies with FCCM (3–5). While no
definite evidence is suggested to correlate between hemorrhagic
risk and size, age, sex, multiplicity or associated DVA, prior
hemorrhage and brainstem CCM location were found to be the
only significant risk factors for CCM hemorrhage (6, 7). Whereas
in other vascular malformations (i.e., aneurysms, arteriovenous
malformations) grading systems have been established to
estimate the risk of intracerebral hemorrhage (ICH), so far no
grading system exists in the literature to serve as a valuable aid
in the clinical decision as to whether perform conservative or
surgical treatment in patients with CCM (8–10).
To date, irrespective of location, asymptomatic CCM are
mainly observed (Class III, Level B) (11, 12). Microsurgical
resection might be considered in patients with asymptomatic
CCM in non-eloquent areas to prevent future hemorrhage when
lifestyle, occupation and the psychological burden outweigh the
risk of surgical morbidity (Class IIb, Level C) (12). For patients
with incidental diagnosis of mCCM, microsurgical resection
is not recommended, given the risk, as well as the morbidity
associated with the multiple surgical approaches (Class III, Level
B) (11). Surgical resection is recommended in patients with
symptomatic CCM located in non-eloquent areas, which present
with new focal neurologic deficit (Class IIb, Level B), recurrent
hemorrhage and medical refractory epilepsy (Class IIa, Level B)
(12). In these cases, surgery is generally safe and can prevent re-
bleeding on one hand and show efficacy for control of epilepsy on
the other hand (13–16).
As the clinical course of patients withmCCM is unpredictable,
there is controversery whether or not active, serial clinical and
radiological follow-up should be recommended (11, 12, 17). As
little data is available on this issue, indication and timing of
follow-up imaging in patients with CCM as well as mCMM is
based on individual judgment, insurance and patient preferences
for now (12). Since no data exists in the literature on follow-
up strategies of patient with mCCM, the objective of this study
was to critically question whether active follow-up by serial
imaging has an impact on clinical decision making in patients
with mCCM and can prevent CCM hemorrhage in the further
course. Our data of our patient cohort with single CCM will be
reported separately.
Abbreviations: CCM, cerebral cavernous malformations; MRI; magnetic
resonance imaging; cMR, cerebral magnetic resonance imaging; FCCM,
familial cerebral cavernous malformations; ICH, intracerebral hemorrhage;
SWI, susceptibility-weighted imaging; mCCM, multiple cerebral cavernous
malformations.
MATERIALS AND METHODS
Patient Population
Retrospective single-center study, encompassing all patients with
CCM that presented at the Department of Neurosurgery at the
University Hospital Zurich between 2006 and 2016. Patients
fulfilling the following criteria were eligible and included: (1)
radiological or histological diagnosis of ≥ 2 CCM (=mCCM)
(2) follow-up data were available. Radiological and histological
diagnosis of mCCM were confirmed either by a senior
neuroradiologist and/or neuropathologist.
Data Collection
The patient’s medical history was analyzed for age, gender and
clinical symptoms (focal neurologic deficit and/or epilepsy).
Headache was not considered as a clinical symptom of CCM
bleeding in this study. In addition, date of first diagnosis, date
of first contact to a neurosurgical department, date of last follow-
up, as well as the number and dates ofMRI studies were collected.
MRI studies always comprised at least T1-weighted imaging
(with and without contrast enhancement), T2-weighted imaging,
and gradient echo sequences in all three planes (axial, coronal,
and sagittal) or susceptibility-weighted imaging (SWI). MRI-
studies were analyzed in regards of CCM location (supratentorial,
infratentorial, spinal) and CCM number, considering the natural
course with decrease or increase in size and de novo-synthesis. A
CCM-related hemorrhage was defined with radiological evidence
(CT or MRI) of subacute or acute hemorrhage compared to
previous imaging. In patients with initial ICH suspicious of
CCM hemorrhage, the diagnosis of CCM was either confirmed
by imaging during follow-up or after CCM resection in the
further course. The dates and indications for each surgical
intervention were obtained, as was the type of patient contact—
being either elective (out-patient consultation) or emergency
(in-patient consultation/emergency room).
Patient Management
At our department, we usually do not operate on asymptomatic
patients with incidental diagnosis of CCM. We consider
complete surgical resection in symptomatic patients with first-
ever hemorrhagic or epileptic presentation if the CCM is
localized non-eloquent and can be removed with a small risk
for postoperative morbidity. In symptomatic patients with deep-
seated or (very) eloquent CCM (e.g., brain stem, basal ganglia)
a more conservative attitude is taken, and we restrain from
operating after the first hemorrhage or when little/spontaneously
improving neurological deficits occur. In our department
microsurgical resection is the preferred treatment option and
stereotactic radiosurgery is not applied in patients with CCM.
We do perform routine radiological and clinical follow-up yearly
in patients with mCCM, comprising both MRI studies and
consultation with a neurovascular surgeon. Physical as well as
neurological examination are performed to determine whether
a newly discovered CCM or increase in size of a CCM is truly
asymptomatic or whether a patient has experienced a history of
seizures or an undiagnosed neurological deficit.
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TABLE 1 | Baseline patient characteristics.
Age in years (mean ± SE) 45.2 ±2.4
Sex
Male
Female
42
31
57.5%
42.5%
Location*
Supratentorial
Infratentorial
Spinal
66
50
2
90.4%
68.5%
2.7%
Number of CCM
≤ 5
6–25
≥ 25
43
16
14
58.9%
21.9%
19.2%
Symptomatic
- Epilepsy
- Neurological deficit
Asymptomatic
46
21
34
27
63.0%
28.8%
46.6%
37.0%
Follow-up time in years (mean ± SE) 6.8 0.85
CCM, cerebral cavernous malformations; SE, standard error. *Does not add up to 100%
as most patients with mCCM presented lesions in multiple compartments.
Ethical Considerations
The study was approved by the Cantonal Ethics Committee
(KEK-ZH; application number 2017-00330).
Statistical Analysis
The software used for descriptive statistical analysis was Stata
v14.2 for Mac (StataCorp, College Station, Texas, USA).
RESULTS
Four hundred and six patients with CCM were seen at our
institution and 73 (18.0%) patients harbored mCCM, fulfilled the
above criteria for this study, and were included in the analysis
(Figure 1). Follow-up data were available for all 73 patients with
mCCM.
Patient Population
The mean age at first diagnosis was 45.2 years (± 2.4 SE);
57.5% of the patients were male (Table 1). CCM were present
in the supratentorial (90.4%), infratentorial (68.5%) and spinal
compartments (2.7%). Forty-three patients (58.9%) harbored ≤
5 CCM; whereas in 16 patients (21.9%) 6-25 CCM and in 14
patients (19.2%) ≥25 CCM were found. Twenty-seven patients
(37.0%) stayed free of symptoms during follow-up, 46 patients
(63.0%) presented with either seizures (n = 21, 28.8%) and/or
neurological deficits (n = 34, 46.6%). The mean follow-up was
6.8 (± 0.85 SE) years per patient (range 0.12–35.0 yrs). The total
follow-up time was 500.5 person-years.
Clinical Management—Conservative and
Operative Treatment
Conservative treatment was performed in 43 patients, while 30
patients underwent surgical extirpation of at least one CCM
lesion (Figure 1). The length of follow-up was 10.3 (±1.6 SE)
in the operated and 4.5 (±0.7 SE) years per patient in the non-
operated patient group. Among the 30 patients that underwent
surgery, 43 surgical procedures were performed in total. Amongst
the 43 surgical interventions that were performed, in 40 cases
the patient was symptomatic and presented with either new
focal neurological deficits due to CCM (re-)bleeding (n = 35)
or intractable epilepsy (n = 5). In only three instances surgery
was performed in patients who were asymptomatic regarding the
CCM that was resected; in these cases, surgery was performed due
to a giant size of the lesion at first diagnosis (n= 1) or increase in
size during follow-up (n= 2).
At time of first patient contact surgical resection of CCM was
performed in 14 patients and 14 instances. During follow-up in
21 patients and in 29 instances surgical treatment was performed.
Among these 21 patients, that underwent treatment during
follow-up 38.1% (n = 8) had already undergone CCM resection
at least once. In two patients, CCM extirpation and hematoma
evacuation was performed four and five times, respectively, due
to recurrent CCM bleeding with acute neurological deficits.
Surgical Intervention Due to New Focal
Neurological Deficits
Among the 35 surgical interventions that were performed due
to CCM bleeding with new focal neurological deficits, in 30
instances (85.7%) patients presented to the emergency unit with
acute CCM bleeding and severe neurological deficits, whereas in
five instances (14.3%) patients were referred to our department
for a second opinion on surgical treatment options [n= 4 due to
(re-)bleeding of pontine CCM and n= 1 due to bleeding of a CM
in the spinal cord].
Amongst the 35 surgical interventions that were performed
due to CCM bleeding with new focal neurological deficits, in 13
patients and 13 instances surgical treatment was performed after
first diagnosis of CCM, whereas in 16 patients and 22 instances
surgical intervention was performed during follow-up. Among
the 22 instances where surgery was performed during follow-
up, in 19 instances (86.4%) the patient presented themselves at
the emergency room and in three instances (13.6%) the patients
were referred to our department for second-opinion on surgical
treatment options [n= 3 due to (re-)bleeding of pontine CCM].
Surgical Intervention Due to Intractable
Epilepsy
Considering the five instances, where surgery was performed due
to intractable epilepsy, all patients (n = 4) were seen during
consultation and decision for surgery was done during follow-
up. In one patient, surgery was performed twice due to intractable
epilepsy. None of the patients stayed seizure free after surgery.
Surgical Intervention in Asymptomatic
Patients
Three patients were operated on asymptomatic lesions. In those,
indication for surgery was done after first diagnosis in one
patient (Case 1) and during follow-up in two patients (Case
2/3): Case 1: Surgery was performed in a young child, who
showed among mCCM one fronto-basal CCM measuring 6 ×
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FIGURE 1 | (A) Analyzed study cohort: From 406 patients with CCM, 73 (18.0%) patients harbored mCCM; n = 30 were operated and n = 43 patients were not
operated. Forty-three surgical interventions were performed in total. Forty surgical interventions were performed in symptomatic patients and 3 surgical interventions
were performed in asymptomatic patients. (B) Timepoint of surgical intervention: 14 surgical interventions were performed at first diagnosis and 29 surgical
interventions were performed during FU. (C) Surgical Interventions due to CCM bleeding with FND: In 13 patients and 13 instances surgical interventions were
performed at first diagnosis; whereas in 16 patients and 22 instances surgical intervention were performed during FU; CCM, cerebral cavernous malformations;
np, number of patients; no, number of operations; FU, follow-up; FND, focal neurological deficits.
3 cm with close proximity to basal ganglia. Case 2: Surgery was
performed in a young adult, who showed an increase in size
of an asymptomatic CCM lesion in the left frontomedial gyrus
measuring 2.3× 2.3 cm during follow-up. Case 3: Surgery was
performed in a young adult with residual right-sided hemiparesis
due to bleeding of a left-sided ventral pontine CCM (and
resection 2 years previously), who showed during follow-up an
increase in size of a CCM in right anterior putamen.
Impact of Active Follow-Up on Surgical
Decision Making
In summary, during 500.5 follow-up years in total in only 2/73
patients with mCCM (2.7%) surgical intervention was performed
due to proactive follow-up by MRI, although patients were
asymptomatic, regarding the CCM lesion that was resected.
Among the 35 instances where surgery was performed due
to CCM (re-)bleeding with new focal neurological deficits in
30 instances (85.7%) patients presented to the emergency unit.
During follow-up, the percentage of patients presenting at the
emergency unit due to CCMbleeding with new focal neurological
deficits stayed high with 86.4%; in three instances (13.6%) the
patients were referred to our department for second-opinion on
surgical treatment options during follow-up. No patient with
CCM (re-)bleeding and new focal neurological deficit was seen
during routinely performed follow-up.
DISCUSSION
The course of patients with mCCM is heterogeneous, as some
present with stable lesions for many years, while in others lesion
size and number increases or less often decreases over time.
To date, there is no consensus on the best management for
mCCM either by active follow-up and serial imaging, or by
specific imaging only in case of new onset of clinical symptoms
(uncommon headache, neurological deficit, or seizure) (12, 17,
18). As little data is available on this issue, indication and timing
of follow-up imaging is based on individual judgment, insurance
and patient preferences for now, and relatively little evidence is
available to make recommendations (12, 17, 18).
Follow-Up Strategy
For patients with single but also multiple CCM we suggested
previously to perform an initial MRI postoperatively or days
after the first hemorrhage, and a follow-up MRI 2–3 months
afterwards. Yearly MRI were considered for all patients with or
without surgery and should be performed in a neurosurgical
experienced center (5). This recommendation was based on
multiple earlier recommendations (12, 17). Considering the
present data, however, we now focus on thorough patient
education about their disease and its natural course. Given
the fact that the risk for a detrimental hemorrhage is
generally very low (3–5), we suggest no active follow-up in
asymptomatic patients with mCCM who feel comfortable about
this. Patients receive detailed contact information for our
emergency department and can contact us 24/7 in case of new-
onset of symptoms. For patients that are more concerned and
request a more proactive follow-up, we offer this according to our
previous follow-up plan, outlined above.
In patients with asymptomatic but growing lesions, one might
feel less confident about not proactively following those patients
by serial imaging. It must be emphasized, however, that increase
in lesion size does not indicate higher risk of hemorrhage, and
the decision to operate is only rarely based on lesion growth in
otherwise oligo- or asymptomatic patients (19). In this particular
situation, the follow-up plan should be decided individually on
a case-to-case basis, but we also consider abstaining from serial
imaging an adequate option here.
Follow-up should be performed in a neuroscience experienced
center—neurologists as well as neuroradiologists can follow
stable patients. Patients with symptomatic epilepsy should be
supervised by neurologists. Patient referral to a neurosurgeon
should be considered for evaluation of symptomatic patients or
progressive lesions, as the only treatment option proven to be
effective is surgical.
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Whereas the percentage of patients presenting with ICH due
to CCM hemorrhage at first diagnosis is hard to minimize, the
aim of routinely performed follow-up MRI in patients which
harbor mCCM is to prevent CCM hemorrhage in the further
course by early surgical recommendation based on patients and
radiographic factors. However, a model based on patients and
radiographic factors, which predicts the lifetime rupture risk of
CCM in each individual case in order to decide whether surgical
treatment should be recommended or not is missing in the
literature—consecutively the therapeutic relevance of routinely
performed follow-up MRI is very limited.
In this study, our patient cohort with 18.0% (n = 73)
of the patients harboring mCCM is comparable to other
published data where the presence of multifocal lesions was
described in 10–31% of all cases (20). During 500.5 follow-
up years in total, routine follow-up MRI in asymptomatic
patients led to an indication for surgery in only 2/73 patients
(2.7%) with mCCM. Furthermore, these two cases may need
to be critically discussed if surgical intervention was really
necessary at all—a spontaneous decrease could have been
awaited first. In a 25-year-old patient, without any clinical
symptoms, a CCM measuring 2.3 × 2.3 cm in left frontal
gyrus was resected due to increase in size during follow-
up. Maybe a spontaneous decrease could have been awaited
first. In a 23-year-old patient with right-sided hemiparesis
due to bleeding of a left-sided ventral CCM of the pons
and resection in 2007, surgical resection of a CCM in right
anterior putamen was performed due to increase in size.
A psychological aspect was considered in this context since
the patient had already experienced CCM bleeding and was
anxious about new focal neurological deficits due to a new
CCM bleeding. Of note, in the non-operated group with 43
patients, 14 patients (32.6%) showed a notable increase in
size of at least one CCM lesion during follow-up, but none
of them experienced CCM bleeding with focal neurological
deficits.
During follow-up, the percentage of patients presenting at the
emergency unit due to CCMbleeding with new focal neurological
deficits stayed high with 86.4%; in three instances [13.6%; n = 3
due to (re-)bleeding of pontine CCM] the patients were referred
to our department for second-opinion on surgical treatment
options during follow-up. No patient with CCM (re-)bleeding
and new focal neurological deficit was seen during routinely
performed follow-up.
During the last decade, there has been a controversy whether
surgical resection in patients with mCCM and intractable
epilepsy should be performed. The presence of mCCM has been
shown as predicator of seizure persistence following surgery (15).
In our study 4 patients with mCCM underwent surgery due to
intractable epilepsy- none of the patients stayed seizure free after
surgery.
Considering our data, where routinely performed cMRI
had a consequence in only 2/73 (2.7%) asymptomatic patients
during 500.5 follow-up years in total, routinely performed
follow-up MRI in asymptomatic patients with mCCM is highly
questionable as there is no evidence for therapeutic relevance.
Furthermore, in case of CCM (re-)bleeding with new focal
neurological deficits the patient will most likely present to the
emergency unit. Given the fact, that so far no grading system
exists for patients with CCM, indication for surgical intervention
will only very rarely be performed during consultation in
asymptomatic patients. A model based on patients and
radiographic factors, which predicts the lifetime rupture risk of
CCM in each individual case in order to decide whether surgical
treatment should be recommended or not is urgently needed—
and could thus dramatically increase the therapeutic relevance
of routinely performed follow-up MRI on the one hand and
decrease the morbidity due to CCM hemorrhage on the other
hand.
In the end, a psychological aspect has to be taken into
consideration and patient education plays a major role. Patients
who have been actively followed with routinely performed
MRI during the last years, might want to proceed with active
follow-up based on the idea to achieve certainty over the
growth and hemorrhage habit of their CCM lesions. One
has to point out to the patients, that no certainty over the
growth and hemorrhage habit of their CCM is given and
that multiple MRI during lifetime might have an adverse
effect on his/her health—as recent findings raise concerns
about the context in which gadolinium deposits in the
brain (21).
Limitations of our study are: (I) the well-known
methodological limitations of retrospective and single-center
cohorts (II) relatively small and heterogenous cohort with
mCCM (n = 73 patients) (III) a potential selection bias since
patients with asymptomatic lesions (i.e., CCM hemorrhage
without neurological deficits) or a poor preoperative functional
status might not have been brought to our attention (IV) the
small size of our patient cohort does not offer the opportunity
to propose and establish clinical and radiological risk factors
for CCM hemorrhage in patients with mCCM (V) despite the
topic of follow-up management being of likewise high relevance
to patients with single CCM, this is a distinct group of patients
and—as such—their management can only be compared to
a certain extent to the management of patients harboring
multiple CCM and no recommendations are made within this
manuscript. Taslimi et al. point out in their meta-analysis,
the increased risk of hemorrhage in brainstem CM, as well as
rehemorrhage being significantly higher within the first two
years after hemorrhage in patients with CCM (22). Horne et al.
propose based on their meta-analysis a risk stratification of
patients with CCM into four groups [ICH or FND presentation
with brainstem CCM (I) or other CCM location (II), as well
as other presentation with brainstem CCM (III) or other
CCM location (IV)] to predict the 5-year risk of ICH (7).
The above-mentioned meta-analyses have to be considered,
when proposing a follow-up scheme for patients with single
CCM. Data of our patient cohort with single CCM will be
published separately and we will try to establish a grading
system that can be used in clinical practice in patients with
single CCM.
The following illustrative case serves to demonstrate
that follow-up imaging can be futile in patients with
mCCM.
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FIGURE 2 | Illustrative case report: Axial (A) and Sagittal (B) sections of
routinely T2-weighted/FLAIR MRI. Axial (C) and Sagittal (D) sections of
T2-weighted/FLAIR MRI and Axial (E) and Sagittal (F) cCT showing cerebellar
CCM bleeding–routinely performed MRI (A,B) was performed 7 weeks
previously.
Illustrative Case Report
Fifteen-year old boy with a cerebellar CCM bleeding and
diagnosis of multiple infra- and supratentorial CCM at the age
of 15.2. At the age of 25 years the patient presented himself
at the emergency unit at our Neurosurgical Department with
hemiparetic symptoms on the right-side due to CCM bleeding
at the left caudate nucleus. Surgical resection was indicated and
performed. In addition, the patient underwent routine cMRI
controls every half a year. Nevertheless, the patient presented
to our emergency unit five times in total due to CCM bleeding
with new focal neurological deficits. Up to date, he underwent an
additional resection of a CCM on the left cerebellar hemisphere,
a resection of a lesion in the left temporal side and for a
second time a CCM resection in the left cerebellar hemisphere.
During the last ten years, 20 cerebral imaging were performed—
nevertheless routinely performed cerebral imaging had no impact
on prevention of CCM bleeding. The shortest duration between
routinely performed follow-up MRI showing stable conditions
and severe CCM bleeding with acute neurological deficits was
just seven weeks (Figure 2).
CONCLUSION
Active follow-up by serial imaging is highly questionable and
will most likely not have any impact on clinical decision making.
Thus, patient education and imaging studies in the setting of new
clinical symptoms may be superior to a rigid follow-up imaging
schedule in patients with mCCM.
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